로딩 중…
지수 로딩 중…
SAMSUNG EPIS HOLDINGS Co., Ltd.
0126Z0· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩429,000-5.40%
2026-06-19
Price Chart
SAMSUNG EPIS HOLDINGS Co., Ltd.
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 10.67T KRW |
| Revenue | 251.69B KRW |
| Net Income | -31.38B KRW |
| Total Assets | 7.72T KRW |
| Net Assets | 5.79T KRW |
| Value | |
| P/B | 1.84x |
| P/S | 42.41x |
| FCF Yield | -1.03% |
| Profitability | |
| ROE | -0.54% |
| ROA | -0.41% |
| Op. Margin | -25.29% |
| Financial Health | |
| Debt Ratio | 33.28% |
| Total Debt | 282.00B KRW |
| FCF | -110.08B KRW |
| Cash | 131.30B KRW |
| Current Ratio | 1.36x |
| Performance | |
| 1M Return | -7.64% |
| From 52W High | -44.50% |
| 1Y MDD | -45.42% |
| Trading | |
| Volume | 61,585 shares |
| Foreign Own. | 7.05% |
| Per Share | |
| EPS | 21,211 KRW |
| BPS | 241,829 KRW |
Company Info
Samsung Episholdings is a bio investment holding company established in 2025, spun off from Samsung Biologics, and is engaged in biotechnology platform development. The company plans to intensively foster new businesses by leveraging its experience in growing its subsidiary, Samsung Bioepis, into a global top 5 biosimilar development company within 10 years through an R&D-focused biotech strategy. Samsung Bioepis has successfully developed and launched 11 biosimilar products, the most worldwide, demonstrating successful biosimilar development and commercialization. The company is headquartered in Yeonsu-gu, Incheon.